InMed’s INM-901 shows statistically significant reduction in neuroinflammation in long-term preclinical study of Alzheimer’s disease

• INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer’s disease

• Statistically significant reduction in neurodegeneration marker, neurofilament light chain (‘NfL’)

• The mRNA profile showed a decrease in several key neuroinflammatory genes in the brain

Vancouver, British Columbia–(Newsfile Corp. – January 21, 2025) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces positive long-term results in vivo preclinical study of Alzheimer’s disease (‘AD’). In the study, INM-901 showed a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to the development and progression of Alzheimer’s disease.

The results of a long-term study of INM-901 in a well-characterized Alzheimer’s disease model showed the following:

• Improved cytokine profile – Groups treated with INM-901 showed a dose-dependent and statistically significant decrease in plasma pro-inflammatory cytokines such as TNF-α, IL-1ß and INF-γ. Cytokine networks, when deregulated, can contribute to tissue inflammation.

• Reduction of biomarkers of neurodegeneration – INM-901 showed a dose-dependent and statistically significant decrease in plasma neurofilament light chain (‘NfL’) for the high-dose group. NfL is a protein released from neurons in response to injury or disease. NfL levels are used to assess cellular damage in neurodegenerative diseases.

• A study supported by mRNA data – mRNA assessments showed a decrease in several key neuroinflammatory genes in the brain, such as GFAP, CD-33 and TLR-2, further supporting the overall results of the study.

dr. Eric Hsu, InMed’s senior vice president of preclinical research and development, commented, “We are very encouraged by the data from our long-term preclinical study of INM-901. Overall, our data demonstrated a reduction in several neuroinflammatory markers in an amyloid-induced Alzheimer’s disease model , suggesting that INM-901 may reduce neuroinflammation INM-901’s ability to actively reduce inflammation is an exciting development, as neuroinflammation has emerged as a promising new drug target beyond existing AD treatments focused primarily on removing amyloid beta plaques and tau protein tangles.” dr. Hsu continued, “Over the last decade, the medical community has witnessed remarkable progress in understanding the pathology of Alzheimer’s disease; it is a multidimensional disease affected by several factors that influence its progression and the degenerative nature of human cognition. InMed’s earlier data suggest that INM-901 can affect multiple pathological factors, making it a very promising drug candidate.”

The company is evaluating additional parameters from this long-term period in vivo study and conducting further molecular analyzes to better define the mechanisms of action and the potential role of INM-901 in the treatment of AD. Analyzes will focus on the following areas via mRNA, protein and histological measurements:

• Levels of receptor involvement: CB1/CB2 and PPAR;

• Neuritogenesis: evaluate markers for neuronal differentiation and neuronal function; and

• Neuroprotection: assessment of stress response and cellular growth/survival.

The company is expected to complete analyzes of these aspects of the study in the coming weeks.

INM-901: Summary of the program to date

INM-901 is a proprietary small molecule drug candidate for Alzheimer’s disease with potentially multiple mechanisms of action. Key features of the INM-901 include:

• shows reduced neuroinflammation and improved neurite growth and neuronal function, indicating the potential to repair damage caused by Alzheimer’s disease;

• is a preferential CB1/CB2 receptor signaling agonist and has been shown to have neuroprotective effects, helping to protect neurons in the brain from damage and cell death;

• affects peroxisome proliferator-activated receptors (“PPARs”), which have been shown to play an important role in diabetes and are also considered one of the potential therapeutic targets for neurodegenerative disorders such as Alzheimer’s disease;

• can be administered orally and achieve therapeutic levels in the brain comparable to those obtained by intraperitoneal injection, offering many potential advantages over the routes of administration of currently approved products; and

• shows significant improvement in cognitive function, memory, locomotor activity, anxiety-based behavior, and auditory awareness in long-term preclinical behavioral studies.

To learn more about InMed’s INM-901 program in the treatment of Alzheimer’s disease, please visit our website: https://www.inmedpharma.com/pharmaceutical/inm-901-for-alzheimer-disease/

The role of neuroinflammation in Alzheimer’s disease

Recent research highlights neuroinflammation as a potentially critical factor in the onset and progression of Alzheimer’s disease. The presence of inflammation and associated brain neurodegeneration demonstrates a causal link between neuroinflammation and Alzheimer’s disease.

Cytokines are proteins that play a key role in communication between cells and in the regulation of the immune response. Proinflammatory cytokines, such as TNF-α, IL-1ß and INF-γ, promote inflammation and are involved in the pathogenesis of Alzheimer’s disease. Research shows that these cytokines are released during the progression of Alzheimer’s disease. Decreasing pro-inflammatory cytokines can slow down or moderate the inflammatory process, preventing neurodegeneration and progression of Alzheimer’s disease.¹

While neuroinflammation may initially have a protective role, continued activation of immune cells

can worsen neuronal damage and accelerate the disease process. Given its central role, targeting neuroinflammation is emerging as a promising therapeutic approach for Alzheimer’s disease. Efforts are underway to develop drugs that modulate microglial activity, reduce cytokine levels, and promote a protective immune response.

¹Article from the Alzheimer’s Association Library: Inflammation as a Central Mechanism of Alzheimer’s Disease

About InMed:

InMed Pharmaceuticals is a pharmaceutical company focused on developing a number of proprietary small molecule drug candidates that target CB1/CB2 receptors. InMed’s program consists of three separate programs in the treatment of Alzheimer’s disease, eye and dermatological indications. For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are often, but not always, identified by words such as “expects,” “anticipates,” “believes,” “intends,” “potential,” “may,” “would” and similar expressions. Such statements, because they are based on management’s current expectations, inherently involve numerous risks, uncertainties and assumptions, both known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to numerous risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this press release includes, but is not limited to, statements regarding: the efficacy of INM-901, the ability of INM-901 to treat AD, the marketability and use of INM-901, the results of a further study of INM-901 as well as the assessment of additional parameters from this long-term in vivo studying and developing a number of proprietary small molecule drug candidates for diseases with high unmet medical needs.

In addition, there are known and unknown risk factors that could cause InMed’s actual results, performance or achievements to differ materially from future results, performance or achievements expressed or implied by the forward-looking information contained herein. A full discussion of the risks and uncertainties facing InMed’s business is published in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission at www.sec.gov.

All forward-looking information contained herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to make public the results of any revision of any such forward-looking information. future contained here. to reflect future results, events or developments, unless required by law.

To view the original version of this press release, visit https://www.newsfilecorp.com/release/237884